Assessment Status | Awaiting full HTA submission from Applicant |
HTA ID | 23051 |
Drug | Fenfluramine |
Brand | Fintepla® |
Indication | Fenfluramine (Fintepla®) is indicated for patients (two years of age and older) with Lennox-Gastaut Syndrome as an add-on therapy to other anti-epileptic medicines. |
Assessment Process | |
Rapid review commissioned | 09/08/2023 |
Rapid review completed | 14/09/2023 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fenfluramine for this indication compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE | 29/09/2023 |
Pre-submission consultation with Applicant | 07/11/2023 |